850870 | C12-200
1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
Product is provided for Research Use Only intended for seeking Food and Drug Administration’s (FDA) approval under The Hatch-Waxman Act (formally known as the Drug Price Competition and Patent Term Restoration Act of 1984).
This product is available for shipping within the United States only. International shipping is not available.
C12-200
1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)
C12-200 is considered a branched-chain ionizable lipidoid used to prepare lipid nanoparticles (LNPs) to deliver siRNA, saRNA, and mRNA primarily to the liver. Below is a sample of recent studies conducted using C12-200:
- Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors1
- Role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA2
- Bile-acid containing lipid nanoparticles enhance extrahepatic mRNA delivery3
References:
1. Shubaash Anthiya, Süleyman Can Öztürk, Hamdullah Yanik, Ece Tavukcuoglu, Adem Şahin, Dhrubajyoti Datta, Klaus Charisse, David Moreira Álvarez, María Isabel Loza, Alfonso Calvo, Einar Sulheim, Simon Loevenich, Geir Klinkenberg, Ruth Schmid, Muthiah Manoharan, Güneş Esendağlı, Maria Jose Alonso,Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors, Journal of Controlled Release, Volume 357,2023, Pages 67-83, ISSN 0168-3659,https://doi.org/10.1016/j.jcon....
(https://www.sciencedirect.com/...)
2. Beatriz D. Barbieri, David J. Peeler, Karnyart Samnuan, Suzanne Day, Kai Hu, Hadijatou J. Sallah, John S. Tregoning, Paul F. McKay, Robin J. Shattock,
The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA, Journal of Controlled Release,Volume 374, 2024, Pages 280-292, ISSN 0168-3659,
https://doi.org/10.1016/j.jcon....(https://www.sciencedirect.com/...)
3. Patel, S.K.; Billingsley, M.M.; Mukalel, A.J.; Thatte, A.S.; Hamilton, A.G.; Gong, N.; El-Mayta, R.; Safford, H.C.; Merolle, M.; Mitchell, M.J. Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery. Theranostics 2024, 14 (1), 1-16. DOI: 10.7150/thno.89913.
CAS Registry Number is a Registered Trademark of the American Chemical Society